Updates on Merkel Cell Carcinoma.

Area of Science:

• Oncology
• Dermatology
• Virology

Background:

• Merkel cell carcinoma (MCC) is a rare, aggressive skin cancer linked to the Merkel cell Polyomavirus.
• Increasing incidence and mortality rates highlight the need for improved understanding and treatment.
• Despite recent advances, the natural history and optimal treatments for MCC remain incompletely understood.

Purpose of the Study:

• To summarize recent advancements in the etiology, detection, and management of Merkel cell carcinoma.
• To highlight the shift towards immunotherapy in advanced MCC treatment.

Main Methods:

• Review of recent literature on MCC etiology, diagnosis, and treatment modalities.
• Analysis of evidence supporting immunotherapy, particularly immune checkpoint inhibitors, for advanced MCC.

Main Results:

• Surgical excision with 1-2 cm margins is the current first-line therapy for early-stage MCC.
• Significant evidence supports the efficacy of immunotherapy for advanced MCC.
• Immune checkpoint inhibitors have received recent approval for advanced MCC treatment.

Conclusions:

• Early-stage MCC is primarily managed with surgical excision.
• Immunotherapy represents a significant advancement for patients with advanced Merkel cell carcinoma.
• Further research is needed to fully elucidate MCC's natural history and optimize treatment strategies.